Compared with mice receiving FMT from melanoma patients who did not respond to anti-PD-1 therapy, those that received FMT from responders showed increased infiltration of CD8+ T-cells within tumors and an enhanced effectiveness of anti-PD-1 therapy. The gene discussed is PDCD1; the disease is melanoma.